The era of strict, site-based spirometry for respiratory trials is no longer. Sponsors now have a host of respiratory endpoints to choose from beyond forced spirometry, and trial participants expect turnkey, home-based testing options and fewer site visits. In an environment where achieving reliable and consistent pulmonary function test data was already challenging, how can drug developers successfully navigate the new options and participant expectations?
Why should you care?
- Learn how AI can be leveraged to reduce cost and turnaround times
- Find out how to capture home spirometry without compromising data quality
- Discover new respiratory endpoints that reduce patient burden
-1.png?width=358&upscale=true&name=MicrosoftTeams-image%20(13)-1.png)
-1.png?width=358&upscale=true&name=MicrosoftTeams-image%20(15)-1.png)
